AAV Vector Filler Sequences for Impurity Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Recombinant adeno-associated virus (rAAV) vector purification is complicated by the presence of impurities such as wild-type/pseudo wild-type AAV species, AAV-encapsidated residual DNA, and empty AAV capsids, which are difficult to separate from bona fide vectors during purification, leading to elevated levels of contaminating nucleic acid sequences.
Innovation Solution
Incorporation of filler or stuffer nucleic acid sequences that adjust the length of the vector genome to match the natural packaging limit of the AAV capsid, reducing encapsidation of contaminating nucleic acids and minimizing vector-related impurities, while also being designed to reduce immune response and lack promoter sequences to prevent adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If rAAV vectors are used for gene therapy, then therapeutic efficacy is improved, but impurities such as wild-type AAV, residual DNA, and empty capsids contaminate the vector preparation
Solution Approach 1:
The patent applies preliminary action by designing the vector genome with optimized length (4.0-5.2 kb) and incorporating specific elements (ITR sequences, polyA signals, introns) before production to facilitate subsequent purification. The vector is engineered with features that enable selective purification methods to remove impurities more effectively, addressing the contamination problem before it arises during the purification process.
Solution Approach 2:
The patent applies parameter changes by modifying the vector genome length to fall within the optimal packaging range of 4.0-5.2 kb, which improves capsid packaging efficiency and reduces empty capsids. Additionally, the use of specific ITR sequences and inclusion of regulatory elements changes the molecular parameters of the vector to enhance purification efficiency and reduce impurity levels.
2Quantity of substance
If vector genome length is increased to improve packaging capacity, then more therapeutic genes can be delivered, but encapsidation of contaminating nucleic acids increases
Solution Approach 1:
The patent applies parameter changes by optimizing the vector genome length to 4.0-5.2 kb, which is within the natural packaging limit of AAV capsids. This parameter optimization ensures efficient packaging of the therapeutic gene while minimizing the capacity available for contaminating DNA, thereby reducing encapsidated impurities without sacrificing therapeutic gene delivery capability.
Solution Approach 2:
The patent applies the extraction principle by removing or minimizing elements that would increase vector genome size unnecessarily. The design focuses on including only essential elements (ITR sequences, minimal promoter, therapeutic gene, polyA signal) and excludes non-essential sequences that would increase packaging capacity for contaminants while not contributing to therapeutic efficacy.
3Manufacturing precision
If filler sequences are added to optimize vector length, then vector purity is improved, but vector complexity increases
Solution Approach 1:
The patent applies parameter changes by incorporating filler sequences to adjust the vector genome length to the optimal 4.0-5.2 kb range. These filler sequences are designed with specific properties (lack of promoter activity, absence of polyA signals) that simplify the overall vector design by eliminating the need for additional complex regulatory elements, thereby improving purity without significantly increasing complexity.
Solution Approach 2:
The patent applies local quality by designing filler sequences with specific local properties (no promoter activity, no polyA signals, specific base composition) that differ from other parts of the vector. This localized optimization allows the filler sequences to serve their length-adjustment function while maintaining simplicity and avoiding the introduction of complex regulatory elements elsewhere in the vector construct.
Data Source
AI summary
The present disclosure provides filler or stuffer sequences, compositions thereof including expression cassettes and vectors, such as viral (e.g., AAV) vectors and methods of delivering a therapeutic agent to a mammal and/or treating a disease.